TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.
- About
TEZSPIRE
- Clinical Data
- Safety
- Dosing
& Administration
- Expert Videos,
Access, & Support
*For commercially insured patients only. Eligibility criteria and program maximums apply. See TEZSPIRE.com for full program details.
- Chronic Rhinosinusitis
with Nasal Polyps
- REQUEST A REP
AND/OR AN FRM
MANY PATIENTS WITH CRSwNP ARE INADEQUATELY CONTROLLED1
START HIGHER WITH TEZSPIRE2,3
FIRST & ONLY biologic to target TSLP and help address epithelial-driven inflammation across the upper & lower airway2,3
The mechanism of action of TEZSPIRE has not been definitively established.
TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).2
See how TEZSPIRE can make an impact
Explore Clinical DataOne fixed-dose strength, every 4 weeks2
SEE DOSING INFORMATIONNot an actual patient. For illustrative purposes only. Results may vary.
00:00Hello, I'm Dr Puchalski and I'm an ENT based in South Carolina.
00:05Treating inadequately controlled chronic rhinosinusitis with nasal polyps (also known as CRS-with-NP)
00:10is a significant part of my clinical practice. Here are 5 things you should know about TEZSPIRE,
00:15from indication and efficacy through safety and dosing. Before we start,
00:20let's cover the indication and an important contraindication.
00:25TEZSPIRE® (tezepelumab-ekko) is indicated for the add-on maintenance treatment of adult and pediatric patients
00:30aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
00:35TEZSPIRE is contraindicated in patients with
00:40known hypersensitivity to tezepelumab-ekko or excipients.
00:45Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis)
00:50following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.
00:55have been reported. These reactions can occur within hours of administration,
01:00but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity
01:05reaction, consider the benefits and risks for the individual patient to determine whether
01:10to continue or discontinue treatment with TEZSPIRE. Stay tuned for additional important safety information…
01:15…at the end of this video. Here are five things you should know about TEZSPIRE.
01:20Number one. The mechanism of action of TEZSPIRE.
01:25To understand how TEZSPIRE works, it helps to look at what's driving epithelial-driven inflammation…
01:30…in CRS-with-NP. Factors, including infectious,
01:35allergic, and environmental factors, can disrupt the epithelium, resulting
01:40in the release of thymic stromal lymphopoietin, or TSLP.
01:45TSLP can lead to the activation of multiple inflammatory drivers,
01:50such as IL-5, IL-4, IL-13, and mast cells,…
01:55…which can contribute to various clinical challenges in CRS-with-NP.
02:00TEZSPIRE is the first and only biologic to target TSLP…
02:05…and help address epithelial-driven inflammation across the upper and lower airway.
02:10The mechanism of action of TEZSPIRE has not been definitively established.
02:15Number two: when added to the standard of care in CRS-with-NP,
02:20TEZSPIRE redefined lasting relief. Now let’s look at the clinical evidence behind TEZSPIRE,…
02:25…starting with the WAYPOINT study design. WAYPOINT was a 52-week, phase 3,
02:30randomized, multicenter, placebo-controlled trial. The study included 408
02:35patients of at least 18 years of age whose CRS-with-NP had
02:40been inadequately controlled for at least 12 months before screening,
02:45at a severity level that was consistent with a need for surgery.
02:50Patients were required to be on stable, standard-of-care treatment for at least 30 days
02:55before starting the trial. They also needed documented prior treatment
03:00with systemic glucocorticoids within the previous 12 months or a history of nasal polyp
03:05surgery of any type. Patients with any clinically significant coexisting condition,
03:10other than asthma, were excluded. Patients were randomized 1:1
03:15to receive TEZSPIRE 210 mg every 4 weeks or a placebo.
03:20TEZSPIRE was added onto the standard of care, which included treatment
03:25with intranasal glucocorticoid therapy. The co-primary endpoints were changes from baseline
03:30in total nasal polyp score and biweekly nasal congestion score compared
03:35with placebo at Week 52. Patients receiving TEZSPIRE
03:40experienced a significant 2.01-point greater reduction
03:45in nasal polyp score at Week 52, compared with placebo.
03:50A significant 0.95 greater reduction in nasal congestion score was also observed
03:55in patients receiving TEZSPIRE at Week 52, compared with placebo.
04:00In addition to the co-primary endpoints, TEZSPIRE had significant improvements
04:05in loss of smell compared with placebo through Week 52,
04:10with symptom relief observed as early as Week 2, the first prespecified
04:15timepoint. At Week 52, patients receiving TEZSPIRE achieved
04:20a 65% reduction in the nasal polyposis symptom diary total
04:25symptom score from baseline compared with placebo. The Nasal Polyposis
04:30Symptom Diary Total Symptom Score included an assessment of symptoms
04:35such as nasal congestion, nasal blockage, and difficulty with sense of smell,
04:40among others. Results are descriptive only. Definitive conclusions cannot be made.
04:45Number three. When added to the standard of care in CRS-with-NP,…
04:50...TEZSPIRE impacted patients’ quality of life, as measured by the SNOT-22
04:55total scores. TEZSPIRE had a statistically significant 45-point
05:00reduction in SNOT-22 total score from baseline
05:05to Week 52 compared with placebo, a 5X improvement
05:10in minimal clinically important difference. However, as WAYPOINT was not designed
05:15to evaluate individual components, aggregate improvements should be interpreted carefully,
05:20noting that some SNOT-22 items may lack relevance to CRS-with-NP
05:25patients or overlap with other study endpoints.
05:30Number four: When added to the standard of care in CRS-with-NP, TEZSPIRE redefined lasting control.
05:35In addition to reductions in nasal polyp size, symptoms,
05:40and quality-of-life improvements, TEZSPIRE also demonstrated meaningful reductions
05:45in the need for further intervention. In WAYPOINT, TEZSPIRE significantly reduced
05:50the need for systemic corticosteroid use and/or surgery by 92%
05:55from baseline to Week 52 compared with placebo.
06:00When systemic corticosteroid use and surgery were assessed individually, TEZSPIRE
06:05showed an 88% reduction in the need for systemic corticosteroid use
06:10and a 98% reduction in the need for surgery over 52 weeks
06:15compared with placebo. Note that while the reported P value is unadjusted,
06:20statistical significance was maintained after multiplicity adjustment.
06:25Number five: An established safety profile. Now let’s review the safety profile of TEZSPIRE.
06:30The safety population from WAYPOINT consisted of 203 patients who received at least one dose
06:35of TEZSPIRE during the 52-week placebo-controlled trial.
06:40Looking at adverse reactions seen in at least 3% of patients
06:45and more frequently than placebo, these included nasopharyngitis, upper respiratory
06:50tract infection, epistaxis, pharyngitis, back pain,
06:55influenza, injection site reaction, and arthralgia.
07:00Let’s discuss how TEZSPIRE is given. The recommended dose of TEZSPIRE is 210 mg
07:05administered subcutaneously once every 4 weeks.
07:10TEZSPIRE is available as a pre-filled syringe for healthcare provider administration, or
07:15a pre-filled pen for at-home use following training by a healthcare provider.
07:20If a dose is missed, administer it as soon as possible and resume the usual dosing
07:25schedule, or if the next dose is already due,
07:30administer as planned. IMPORTANT SAFETY INFORMATION. CONTRAINDICATIONS
07:35Known hypersensitivity to tezepelumab-ekko or excipients. WARNINGS AND PRECAUTIONS.
07:40Hypersensitivity Reactions. Hypersensitivity reactions were observed in the clinical trials
07:45(eg, rash and allergic conjunctivitis)following the administration of TEZSPIRE.
07:50Postmarketing cases of anaphylaxis have been reported. These reactions can occur
07:55within hours of administration, but in some instances have a delayed onset (ie, days).
08:00In the event of a hypersensitivity reaction, consider the benefits and risks for the individual
08:05patient to determine whether to continue or discontinue treatment with TEZSPIRE.
08:10Acute Asthma Symptoms or Deteriorating Disease
08:15TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm,
08:20or status asthmaticus. Abrupt Reduction of Corticosteroid Dosage.
08:25Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE.
08:30Reductions in corticosteroid dose, if appropriate, should be gradual
08:35and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated
08:40with systemic withdrawal symptoms and/or unmask conditions previously suppressed by
08:45systemic corticosteroid therapy. Parasitic (Helminth) Infection.
08:50It is unknown if TEZSPIRE will influence a patient’s response against helminth infections.
08:55Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE.
09:00If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth
09:05treatment, discontinue TEZSPIRE until infection resolves.
09:10Live Attenuated Vaccines. The concomitant use of TEZSPIRE and live attenuated vaccines
09:15has not been evaluated. The use of live attenuated vaccines should be avoided
09:20in patients receiving TEZSPIRE. ADVERSE REACTIONS. The most common
09:25adverse reactions (incidence ≥3%) chronic rhinosinusitis with nasal
09:30polyps: nasopharyngitis, upper respiratory tract infection, epistaxis,
09:35pharyngitis, back pain, influenza, injection site reaction and arthralgia.
09:40USE IN SPECIFIC POPULATIONS. There are no available data on TEZSPIRE use
09:45in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage,
09:50or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies
09:55such as tezepelumab-ekko is greater during the third trimester of pregnancy;
10:00therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.
10:05INDICATION. TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric
10:10patients aged 12 years and older with inadequately controlled chronic rhinosinusitis
10:15with nasal polyps (CRSwNP).
10:20I hope the data reviewed today provided useful insight as you consider how TEZSPIRE may benefit
10:25the chronic rhinosinusitis patients with nasal polyps in your care.
10:30Visit TEZSPIREHCP.com to learn more about TEZSPIRE.
10:39Music Ends.
TSLP=thymic stromal lymphopoietin.
Thank you for signing up.
Important Safety Information
Collapse
CONTRAINDICATIONS
Known hypersensitivity to tezepelumab-ekko or excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.
Acute Asthma Symptoms or Deteriorating Disease
TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
Abrupt Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Parasitic (Helminth) Infection
It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
Live Attenuated Vaccines
The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥ 3%) are:
- Asthma: pharyngitis, arthralgia, and back pain.
- Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia
USE IN SPECIFIC POPULATIONS
There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.
INDICATION
TEZSPIRE is indicated for:
- the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus
- the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)
Please see full Prescribing Information, including
Patient Information and Instructions for Use.
You may report side effects related to AstraZeneca products 
Opens new window. 
Opens new window
Important Safety Information
+
Important Safety Information
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.
Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-105253, AstraZeneca Pharmaceuticals LP. 7. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.
Reference: 1. Data on File. US-105253, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.
Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.
References: 1. Price D, Dale P, Elder E, Chapman KR. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. J Asthma. 2014;51(2):127-135. 2. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 3. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 4. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 5. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 8. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.
References: 1. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915-932. 6. Data on File. REF-263922, AstraZeneca Pharmaceuticals LP. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 8. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 9. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 10. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 11. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.
References: 1. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 7. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 11. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.
References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 10. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 12. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 13. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 14. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 15. Data on File. US-98281, AstraZeneca Pharmaceuticals LP.
References: 1. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Brace yourselves: the biggest week for asthma attacks is coming. Asthma and Allergy Foundation of America. Published August 25, 2022. Accessed August 5, 2025. https://community.aafa.org/blog/September-Asthma-Peak-brace-yourselves-the-biggest-week-for-asthma-attacks-is-coming. 7. Protect your child against the September epidemic. National Jewish Health. Accessed August 5, 2025. https://www.nationaljewish.org/conditions/health-information/multimedia/living-with-asthma/protect-your-child-against-the-september-epidemic. 8. Sheehan WJ, Patel SJ, Margolis RH, et al. Pediatric asthma exacerbations during the COVID-19 pandemic: absence of the typical fall seasonal spike in Washington, DC. J Allergy Clin Immunol Pract. 2021;9(5):2073-2076. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5.
References: 1. van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy. 2017;72(2):282-290. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.
References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-292218, AstraZeneca Pharmaceuticals LP. 3. Pfaar O, Han JK, Desrosiers M, et al. Onset of action of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study. Presented at: European Rhinologic Society (ERS) 2025 Congress; June 22-25, 2025; Budapest, Hungary. 4. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps [Appendix]. N Engl J Med. 2025;392(12):1178-1188. 5. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178-1188. 6. Chowdhury NI, Mace JC, Bodner TE, et al. Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(12):1149-1155. 7. Data on File. REF-287771, AstraZeneca Pharmaceuticals LP. 8. Data on File. WAYPOINT Clinical study report. Tezepelumab D5242C00001; January 23, 2025.
References: 1. Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149(5):1491-1503. 2. Peters A, Zhao X, Near AM, et al. Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps. Adv Ther. 2025;42(4):1783-1799. 3. Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725-739. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. Ha J-G, Cho H-J. Unraveling the role of epithelial cells in the development of chronic rhinosinusitis. Int J Mol Sci. 2023;24(18):14229. 7. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 8. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56.
This product information is intended for US Healthcare Professionals only.
TEZSPIRE is a registered trademark of Amgen Inc.
and AstraZeneca.
©2026 AstraZeneca. All rights reserved. US-113519 Last Updated 8/26
- Privacy Notice
- Cookie Preferences
- Legal Statement
- Contact Us
- Your Privacy Choices
- Consumer Health Data Privacy Notice
